Antiviral efficacy of RAY1216 monotherapy and combination therapy with ritonavir in patients with COVID-19: a phase 2, single centre, randomised, double-blind, placebo-controlled trialResearch in context

Antiviral efficacy of RAY1216 monotherapy and combination therapy with ritonavir in patients with COVID-19: a phase 2, single centre, randomised, double-blind, placebo-controlled trialResearch in context

Summary: Background: This study aimed to evaluate the efficacy and safety of RAY1216, a novel inhibitor of 3-chymotrypsin-like cysteine protease (3CLpro), in adults with coronavirus disease 2019 (COVID-19). Methods: This phase 2, single centre, randomised, double-blind, placebo-controlled trial inc...

Full description

Bibliographic Details
Main Authors: Bei Wang, Hai-jun Li, Mi-mi Cai, Zhao-xin Lin, Xia-fei Ou, Shu-hua Wu, Rui-huan Cai, Ying-na Wei, Fei Yang, Ya-min Zhu, Zi-feng Yang, Nan-shan Zhong, Ling Lin
Format: Article
Language:English
Published: Elsevier 2023-09-01
Series:EClinicalMedicine
Subjects:
SARS-CoV-2
COVID-19
3-Chymotrypsin-like cysteine protease
RAY1216
Viral shedding time
Efficacy and safety
Online Access:http://www.sciencedirect.com/science/article/pii/S2589537023003668

Internet

http://www.sciencedirect.com/science/article/pii/S2589537023003668

Similar Items